Mammographic breast density can predict risk of lymphedema: JAMA

For the purpose, the researchers collected data from July 16, 2018, to March 3, 2020 from the health records of patients of the Cancer Rehabilitation and Survivorship Program at the Princess Margaret Cancer Centre in Toronto, Ontario, Canada. Participants consisted of women (n=373) who had completed curative treatment for a first diagnosis of breast cancer and who were referred to the program. It also included a sample of patients in the general breast oncology population who were receiving follow-up care at the center during the same period but who were not referred to the program. A sample of of patients in the general breast oncology population who were receiving follow-up care at the center during the same period but who were not referred to the program were also included. 

All patients attended follow-up appointments at the Princess Margaret Cancer Centre from January 1, 2016, to May 1, 2018. The cohort was randomly split 2:1 to group patients into a training cohort and a validation cohort.

Spearman correlation coefficient between measured and predicted volume of lymphedema was calculated. Area under the curve (AUC) values were generated for predicting the occurrence of at least mild lymphedema (volume, >200 mL) and severe lymphedema (volume, >500 mL) at the time of initial lymphedema diagnosis. 

"The findings of this study suggest that mammographic breast density can be used as a prognostic factor for lymphedema risk and provide volumetric estimates for lymphedema severity," concluded the authors. 

The study, "Development and Validation of a Risk Model for Breast Cancer–Related Lymphedema," is published in the journal JAMA Network Open.

DOI: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772800